CJC-1295 with DAC
CJC-1295 with DAC is a long-acting analogue of growth hormone-releasing hormone (GHRH). Its albumin-binding modification prolongs exposure to the compound; human studies measured changes in growth hormone (GH) and IGF-I.
What is documented for this listing
| Compound class | Long-acting GHRH analogue |
| DAC modification | Albumin binding, as described for the preparation studied by Ionescu and Frohman |
| Human study endpoints | GH, IGF-I and pharmacokinetics; no established treatment benefit |
Checks before a research procurement decision
- Match the quoted product name, DAC status, supplied form and exact SKU unit.
- Keep the albumin-binding study preparation separate from the no-DAC or Mod GRF 1-29 label.
- Request the allocated-lot identity method, specification, acceptance criteria and available batch results.
- Confirm storage, packaging, destination requirements and the unit represented by each price-list row.
Wholesale pricing for CJC-1295 with DAC
Wholesale from $1.53
2 / Injectable, 50+ units of this SKU. Wholesale tiers require 100+ total units across the order. Reference snapshot: .
Published price-list tiers
| SKU / form | 10–24 units of this SKU | 25–49 units of this SKU | 50+ units of this SKU |
|---|---|---|---|
| 10 / Injectable | $5.44 | $4.76 | $4.08 |
| 2 / Injectable | $2.04 | $1.78 | $1.53 |
| 5 / Injectable | $3.40 | $2.97 | $2.55 |
The 2/5/10 labels reproduce the source exactly; it does not define their mass or package unit. These reference prices do not confirm stock. A quotation must identify the unit, DAC status, supplied form, allocated lot, analytical results and destination terms.
Research findings and procurement boundary
Literature review checked on . Two primary human studies were selected because they identify CJC-1295 and report GH/IGF-I or pharmacokinetic outcomes. DOI metadata and indexed abstracts were checked through Crossref and Europe PMC; full texts were not reviewed. This is a focused literature overview, not a systematic review or an experiment conducted by Dr. Peptides.
Teichman et al. (2006). Two randomized, placebo-controlled, double-blind trials followed healthy adults aged 21–61 for 28 and 49 days. GH rose 2–10-fold for at least six days and IGF-I 1.5–3-fold for 9–11 days after a single administration; the estimated half-life was 5.8–8.1 days. These were hormone and pharmacokinetic measurements, not evidence of improved strength, recovery or long-term benefit. DOI 10.1210/jc.2005-1536.
Ionescu and Frohman (2006). Healthy men aged 20–40 had GH sampled every 20 minutes overnight before and one week after administration. GH pulses persisted; frequency and magnitude did not change. Trough GH rose 7.5-fold, while mean GH and IGF-I rose 46% and 45%. The defined observation window did not establish a regimen or long-term safety. DOI 10.1210/jc.2006-1702.
DAC and no-DAC are separate evidence questions
| Catalog label | Evidence boundary |
|---|---|
| CJC-1295 with DAC | Albumin-binding study preparation with reported GH/IGF-I and pharmacokinetic observations. |
| CJC-1295 without DAC (Mod GRF 1-29) | The cited papers do not establish the same half-life, albumin binding or hormone response. |
A catalog name alone does not establish sequence, conjugation or supplier-batch equivalence.
Questions about CJC-1295 with DAC
The cited study preparation binds to endogenous albumin, which is associated with prolonged exposure. This differs from interpreting the compound as a short-lived GHRH fragment. The papers do not establish that any material sold under a similar name has the same identity.
No. The reported half-life and GH/IGF-I changes concern albumin-binding CJC-1295. A no-DAC or Mod GRF 1-29 label does not establish the same preparation or response.
The 20 May 2026 price list records $1.53 for the 2 / Injectable row at 50+ units of that SKU, with a minimum of 100+ total units across the order. The source does not define the mass or package unit; the quotation must confirm it.
No. A study result does not identify a supplier lot, its composition, analytical purity or storage history. Those require batch-specific documentation.
No. The studies measured hormones and pharmacokinetics under their own protocols. This research-procurement reference does not provide medical, veterinary, dosing or administration guidance.
Related Pharmaceutical Peptides
BPC-157
Wholesale from $1.80; confirm SKU, allocated lot and available batch documents in the quote.
View Details Pharmaceutical PeptidesIpamorelin
Wholesale from $1.27; confirm SKU, allocated lot and available batch documents in the quote.
View Details Pharmaceutical PeptidesCJC-1295 without DAC (Mod GRF 1-29)
Wholesale from $1.27; confirm SKU, allocated lot and available batch documents in the quote.
View Details Pharmaceutical PeptidesKPV Tripeptide
Wholesale from $2.55; confirm SKU, allocated lot and available batch documents in the quote.
View Details